Enlivex Therapeutics Ltd. (ENLV)

NASDAQ: ENLV · Real-Time Price · USD

1.003

-0.017 (-1.67%)

At close: May 12, 2025, 4:00 PM

1.030

+0.027 (2.69%)

After-hours: May 12, 2025, 7:30 PM EDT

Enlivex Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Selling, General & Admin	4.91	6.14	7.1	6.41	3.7	Upgrade
Research & Development	10.62	19.01	18.69	12.88	6.09	Upgrade
Operating Expenses	15.54	25.15	25.8	19.29	9.79	Upgrade
Operating Income	-15.54	-25.15	-25.8	-19.29	-9.79	Upgrade
Interest & Investment Income	1.07	1.57	0.84	0.12	0.23	Upgrade
Currency Exchange Gain (Loss)	-0.18	-1.22	-4.1	-0.56	-2.26	Upgrade
Other Non Operating Income (Expenses)	0.59	-0.01	-0.01	-0.33	-0.01	Upgrade
EBT Excluding Unusual Items	-14.06	-24.82	-29.08	-20.06	-11.82	Upgrade
Gain (Loss) on Sale of Investments	-	-	-1.98	5.59	-	Upgrade
Gain (Loss) on Sale of Assets	-0.96	-4.24	-	-	-	Upgrade
Pretax Income	-15.01	-29.07	-31.06	-14.47	-11.82	Upgrade
Net Income	-15.01	-29.07	-31.06	-14.47	-11.82	Upgrade
Net Income to Common	-15.01	-29.07	-31.06	-14.47	-11.82	Upgrade
Shares Outstanding (Basic)	21	19	18	18	13	Upgrade
Shares Outstanding (Diluted)	21	19	18	18	13	Upgrade
Shares Change (YoY)	10.44%	0.98%	3.00%	35.62%	52.25%	Upgrade
EPS (Basic)	-0.73	-1.56	-1.69	-0.81	-0.90	Upgrade
EPS (Diluted)	-0.73	-1.56	-1.69	-0.81	-0.90	Upgrade
Free Cash Flow	-13.11	-23.76	-32.08	-19.17	-12.03	Upgrade
Free Cash Flow Per Share	-0.64	-1.28	-1.74	-1.07	-0.91	Upgrade
EBITDA	-14.99	-24.32	-25.02	-18.74	-9.5	Upgrade
D&A For EBITDA	0.55	0.84	0.78	0.55	0.29	Upgrade
EBIT	-15.54	-25.15	-25.8	-19.29	-9.79	Upgrade

Updated Nov 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q